PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11817159

[Epilepsy and sleep].

A Bauerfeind
View original source ↗Export metadata ↓

Abstract

Epilepsy and sleep are intricately associated. Influences of epilepsy on sleep as a result of drug treatment and the vigilance altering effects thereof as well as the temporal distribution and presentation of seizures are considered. The effect of sleep quality on seizure frequency is well known and must play a part in the management of patients with epilepsy. A careful scrutiny of potential sleep disturbing factors such as primary sleep disorders is equally important to the successful management of seizure frequency and of excessive daytime somnolence, which may be a confounding comorbidity in this patient population. The occasionally difficult differential diagnosis of epilepsy and parasomnias is a field in which an interdisciplinary approach between epileptologists and sleep specialists is necessary, video-EEG-polysomnography being an indispensable diagnostic instrument.

Explore related subjects

AnticonvulsantsCerebral CortexDiagnosis, DifferentialElectroencephalographyEpilepsyHumansParasomniasPolysomnographySleep Wake DisordersEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Bauerfeind. 2001. [Epilepsy and sleep].. https://doi.org/10.1024/0040-5930.58.11.656

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗